Investigational drug · Phase 3
Tralesinidase
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for MPS IIIB.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "Tralesinidase"
First trial start
2026
Dec 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tralesinidase", any sponsor or status.
Conditions studied
As listed on its trial records.
- MPS IIIB
Largest trials
Live from ClinicalTrials.gov: studies naming "Tralesinidase" as an intervention, largest first.
- Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B)Pivotal-lookingNot yet recruiting
Spruce BiosciencesIndustry
NCT07579910 · 14 participants (planned) · Start Dec 2026 · Primary completion Aug 2033
Drug: Tralesinidase alfa (TA) · For: MPS IIIB
Spruce BiosciencesIndustry
NCT07733856
Drug: Tralesinidase alfa (TA) · For: Mucopolysaccharidosis Type IIIB; MPS IIIB (Sanfilippo B Syndrome)
Sites: Oakland, California
Newest research
PubMed records naming it or its code names, newest first.
- Safety, pharmacokinetics and CNS distribution of tralesinidase alfa administered via intracerebroventricular infusion to juvenile cynomolgus monkeys.
Pinkstaff J, McCullagh E, Grover A, et al. · Toxicol Rep 2023
- A phase I/II study on intracerebroventricular tralesinidase alfa in patients with Sanfilippo syndrome type B.
Muschol N, Koehn A, von Cossel K, et al. · J Clin Invest 2023
- Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB.
Ellinwood NM, Valentine BN, Hess AS, et al. · J Pharmacol Exp Ther 2022
- BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis.
Yogalingam G, Luu AR, Prill H, et al. · PLoS One 2019
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.